SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
ARNA Analysis & Videos »
ARNA: Bull or Bear?
FDA Calendar: Five Weight Loss Trades
ARNA
|
|
|
+14.72%
in
58 days
(closed on 09/17/09)
<> Below are five small/micro-cap companies from the <font> BioMedReports.com FDA Calendar </font> with late-stage drugs or medical devices in development for prescription weight loss. Nearly two-thirds or 65% of U.S. population is classified as obese or overweight with a three-fold increase in adolescent obesity rates over the past three decades. Obesity is the second leading cause of preventable deaths behind smoking and weight loss is proven to decrease mortality while also improving blood sugar control in diabetics. Over one-third (35%) of people in the U.S. have a lifetime of devel...
|
Extreme FDA Calendar Trades: 18 Stocks Under $5
ARNA
|
|
|
+11.75%
in
18 days
(closed on 07/21/09)
<> Below are extreme trades among companies with stock prices under $5 from the <font> BioMedReports.com FDA Calendar </font> , which includes 232 entries as of 7/3/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissio...
|
FDA Calendar Updates: MITI, KERX, GSK, DYAX, ARNA, PGNX
ARNA
|
|
|
-1.82%
in
25 days
(closed on 07/03/09)
<> Below is a summary of updates to the <font> BioMedReports.com FDA Calendar </font> , which includes a database of about 200 entries. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending late-s...
|
FDA, Clinical Trial Calendar Updates: Weight Loss, Diabetes, and More
ARNA
|
|
|
+17.26%
in
43 days
(closed on 05/14/09)
<> The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA deadline dates. The entries are updated on a daily basis as new information becomes available with a total of 110 entries through 4/1/09. The FDA Calendar includes the following information: company name, ticker, decision d...
|
A Calendar of Expected Clinical Trial Results
ARNA
|
|
|
+17.25%
in
80 days
(closed on 04/01/09)
<> 
The accompanying table [click to enlarge] includes 58 entries of expected clinical trial results in addition to pending FDA applications for new product approvals + a list of companies which will be required to re-submit their applications due to complete response letters from the agency.
See my recent article on 20 emerging healthcare stocks to watch in 2009 for more details on some of the companies included in the accompanying calendar, in addition to the following companies with near-term catalysts in...
|
Staying Neutral on Arena Pharma
ARNA
-38.32%
in
488 days
As such, the idea of lorcaserin for obesity and APD125 for insomnia is fantastic, but both products fall short of blockbusters in our view. This part was added on experimental basis to see the effect. This part was added on experimental basis to see the effect. This part was added on experimental basis to see the effect. This part was added on experimental basis to see the effect. This part was added on experimental basis to see the effect. This part was added on experimental basis to see the effect. This part was added on experimental basis to see the effect. This part was added on experim...
|
BIG STOCK TO GET
ARNA
|
|
|
+0.00%
in
5 hours
(closed on 04/24/07)
shares gained 7.9% after the company said its first-quarter loss widened, due in part to costs related to the Phase III lorcaserin Bloom trial. The first quarter of 2006 also included a $5 million milestone payment under its collaboration with Ortho-McNeil Pharmaceutical Inc. The San Diego biotechnology company had a first-quarter loss of $31.4 million, or 53 cents a share, compared with a loss of $12.7 million, or 30 cents a share, a year earlier. Arena said revenue for the quarter fell 60% to $4.91 million from $12.1 million a year earlier. This company is going to shoot up big. Look at a...
|
BIG STOCK TO GET
ARNA
|
|
|
+0.00%
in
5 minutes
(closed on 04/23/07)
<> shares gained 7.9% after the company said its first-quarter loss widened, due in part to costs related to the Phase III lorcaserin Bloom trial. The first quarter of 2006 also included a $5 million milestone payment under its collaboration with Ortho-McNeil Pharmaceutical Inc. The San Diego biotechnology company had a first-quarter loss of $31.4 million, or 53 cents a share, compared with a loss of $12.7 million, or 30 cents a share, a year earlier. Arena said revenue for the quarter fell 60% to $4.91 million from $12.1 million a year earlier. This company is going to shoot up big. Look a...
|
People Bullish on ARNA
People Bearish on ARNA
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on ARNA |
Be the first to start a discussion and earn 2 points.
More Resources
|
About Arena Pharmaceuticals Inc
- Answers.com
